pulmoПульмонологияPULMONOLOGIYA0869-01892541-9617Scientific and Practical Journal “PULMONOLOGIYA” LLC10.18093/0869-0189-2015-25-6-747-752pulmo-655Research ArticleЗАМЕТКИ ИЗ ПРАКТИКИPRACTICAL NOTESВлияние комбинированной терапии индакатеролом и гликопиррония бромидом на состояние респираторной и сердечно-сосудистой систем у пациентов с хронической обструктивной болезнью легкихRespiratory and cardiovascular effects of combined therapy with indacaterol and glycopyrronium bromide in chronic obstructive pulmonary diseaseЗагидуллинН. Ш.ZagidullinN. Sh.

д. м. н., доцент, профессор кафедры пропедевтики внутренних болезней ГБОУ ВПО «Башкирский государственный медицинский университет» Минздрава России; тел.: (347) 2465397

MD, Assistant Professor, Professor at Department of Propaedeutics of Internal Diseases, Bashkir State Medical University, Healthcare Ministry of Russia; tel.: (347) 2465397

znaufal@mail.ruЗулкарнеевР. Х.ZulkarneevR. Kh.

аспирант кафедры пропедевтики внутренних болезней ГБОУ ВПО «Башкирский государственный медицинский университет» Минздрава России; тел.: (347) 2465397

PhD student at Department of Propaedeutics of Internal Diseases, Bashkir State Medical University, Healthcare Ministry of Russia; tel.: (347) 2465397

y.f.safina@mail.ruСафинаЮ. Ф.SafinaYu. F.

д. м. н., профессор кафедры пропедевтики внутренних болезней ГБОУ ВПО «Башкирский государственный медицинский университет» Минздрава России; тел.: (347) 2465397

MD, Professor at Department of Propaedeutics of Internal Diseases, Bashkir State Medical University, Healthcare Ministry of Russia; tel.: (347) 2465397

zrustem@ufanet.ruАзнабаеваЮ. Г.AznabaevaYu. G.

к. м. н., доцент кафедры пропедевтики внутренних болезней ГБОУ ВПО «Башкирский государственный медицинский университет» Минздрава России; тел.: (347) 2465397

PhD, Associate Professor at Department of Propaedeutics of Internal Diseases, Bashkir State Medical University, Healthcare Ministry of Russia; tel.: (347) 2465397

albert3574@rambler.ruЗагидуллинШ. З.ZagidullinSh. Z.

д. м. н., профессор, зав. кафедрой пропедевтики внутренних болезней ГБОУ ВПО «Башкирский государственный медицинский университет» Минздрава России; тел.: (347) 2465397

MD, Professor, Head of Department of Propaedeutics of Internal Diseases, Bashkir State Medical University, Health care Ministry of Russia; tel.: (347) 2465397

ГБОУ ВПО «Башкирский государственный медицинский университет» Минздрава России: 450000, Республика Башкортостан, Уфа, ул. Ленина, 3РоссияBashkir State Medical University: 3, Lenina str., Ufa, 450000, Bashkortostan Republic, RussiaRussian Federation201528022016256747752Copyright © Загидуллин Н.Ш., Зулкарнеев Р.Х., Сафина Ю.Ф., Азнабаева Ю.Г., Загидуллин Ш.З., 20162016Загидуллин Н.Ш., Зулкарнеев Р.Х., Сафина Ю.Ф., Азнабаева Ю.Г., Загидуллин Ш.З.Zagidullin N.S., Zulkarneev R.K., Safina Y.F., Aznabaeva Y.G., Zagidullin S.Z.Данная работа распространяется под лицензией Creative Commons Attribution 4.0.This work is licensed under a Creative Commons Attribution 4.0 License.https://journal.pulmonology.ru/pulm/article/view/655

Респираторная и сердечнососудистая системы тесно взаимосвязаны, при этом в случае хронической обструктивной болезни легких (ХОБЛ) на их статус может оказать влияние терапия бронходилататорами. На примере 2 клинических наблюдений рассматривается возможность перехода от монотерапии индакатеролом к комбинированной терапии индакатеролом и гликопиррония бромидом с анализом динамики изменений соответствующих респираторных и кардиоваскулярных показателей у пациентов с ХОБЛ тяжелой степени. Продемонстрирована тенденция к уменьшению бронхообструкции, улучшению субъективных ощущений, сократительной способности левого и правого желудочков и вариабельности ритма сердца.

The aim of this article was to investigate respiratory and cardiovascular effects of combined therapy with indacaterol and glycopyrronium bromide in patients with severe chronic obstructive pulmonary disease.

Methods

Methods. Two clinical cases are reported in the article. Both patients were treatment with longacting beta2agonist indacaterol for 3 months followed by 3month treatment with combined therapy with indacaterol and glycopyrro nium bromide. We assessed arterial stiffness, pulse wave velocity rate, the heart rhythm variability, used spirometry and echocardiography, CAT and MMRC scales.

Results

Results. Combined inhalation therapy resulted in significant increase in FEV1 and FVC, reduction in dyspnea, improvement in arterial oxygen saturation. Arterial stiffness was not changed, but the heart rhythm autonomic regulation improved in both patients. A tendency to increase in the left heart ejection fraction was also found.

Conclusion

Conclusion. Our data are consistent with results of other clinical trials of indacaterol and glycopyrronium bromide in patients with chronic obstructive pulmonary disease.

хроническая обструктивная болезнь легкихиндакатеролгликопирронийартериальная жесткостьсократимость правого желудочкавариабельность ритма сердцаchronic obstructive pulmonary diseaseIndacaterolglycopyrronium bromidearterial stiffnessright ventricleheart rate variabilityReferencesGlobal Initiative for Chronic Obstructive Lung Disease (2013) Global strategy for the diagnosis, management and prevention of chronic obstructive pulmonary disease. www.goldcopd.comGlobal Initiative for Chronic Obstructive Lung Disease (2013) Global strategy for the diagnosis, management and prevention of chronic obstructive pulmonary disease. www.goldcopd.comBeeh K.M., Beier J. Indacaterol: a new once daily longacting beta2adrenoceptor agonist. Core Evidence. 2009; 4: 37–41.Beeh K.M., Beier J. Indacaterol: a new once daily longacting beta2adrenoceptor agonist. Core Evidence. 2009; 4: 37–41.Feldman G., Siler T, Prasad N. et al. Efficacy and safety of indacaterol 150 microg oncedaily in COPD: a doubleblind, randomised, 12week study. BMC Pulm. Med. 2010; 10: 11.Feldman G., Siler T, Prasad N. et al. Efficacy and safety of indacaterol 150 microg oncedaily in COPD: a doubleblind, randomised, 12week study. BMC Pulm. Med. 2010; 10: 11.Chapman K.R., Rennard S.I., Dogra A. et al. Longterm safety and efficacy of indacaterol, a longacting β2agonist, in subjects with COPD: a randomized, placebocontrolled study. Chest. 2011; 140 (1): 68–75.Chapman K.R., Rennard S.I., Dogra A. et al. Longterm safety and efficacy of indacaterol, a longacting β2agonist, in subjects with COPD: a randomized, placebocontrolled study. Chest. 2011; 140 (1): 68–75.Dahl R., Chung K.F., Buhl R. et al. Efficacy of a new once daily longacting inhaled β2agonist indacaterol versus twicedaily formoterol in COPD. Thorax. 2010; 65: 473–479.Dahl R., Chung K.F., Buhl R. et al. Efficacy of a new once daily longacting inhaled β2agonist indacaterol versus twicedaily formoterol in COPD. Thorax. 2010; 65: 473–479.Buhl R., Banerji D. Profile of glycopyrronium for once daily treatment of moderatetosevere COPD. Int. J. COPD. 2012; 7: 729–741.Buhl R., Banerji D. Profile of glycopyrronium for once daily treatment of moderatetosevere COPD. Int. J. COPD. 2012; 7: 729–741.Ulrik C.S. Oncedaily glycopyrronium bromide, a longacting muscarinic antagonist, for chronic obstructive pulmonary disease: a systematic review of clinical benefit. Int. J. COPD. 2012; 7: 673–678.Ulrik C.S. Oncedaily glycopyrronium bromide, a longacting muscarinic antagonist, for chronic obstructive pulmonary disease: a systematic review of clinical benefit. Int. J. COPD. 2012; 7: 673–678.Barnes P.J. Anticholinergic Therapy in Obstructive Airway Disease. Ed. by N.Gross. London; 1993: 88–104.Barnes P.J. Anticholinergic Therapy in Obstructive Airway Disease. Ed. by N.Gross. London; 1993: 88–104.Brown J.H., Taylor P. Goodman and Gilman’s the Pharmacological Basis of Therapeutics. Ed. by J.G. Hardman et al. New York; 1996: 141.Brown J.H., Taylor P. Goodman and Gilman’s the Pharmacological Basis of Therapeutics. Ed. by J.G. Hardman et al. New York; 1996: 141.Lange P., Mogelvang R., Marott J.L. et al. Cardiovascular morbidity in COPD: a study of the general population. COPD. 2010; 7: 5–10.Lange P., Mogelvang R., Marott J.L. et al. Cardiovascular morbidity in COPD: a study of the general population. COPD. 2010; 7: 5–10.Konecny T., Park J.Y., Somers K.R. et al. Relation of chronic obstructive pulmonary disease to atrial and ventricular arrhythmias. Am. J. Cardiol. 2014; 15: 114 (2): 272–277.Konecny T., Park J.Y., Somers K.R. et al. Relation of chronic obstructive pulmonary disease to atrial and ventricular arrhythmias. Am. J. Cardiol. 2014; 15: 114 (2): 272–277.Zulkarneev R., Zagidullin N., Abdrahmanova G. et al. Ivabradine prevents heart rate acceleration in patients with chronic obstructive pulmonary disease and coronary heart disease after salbutamol inhalation. Pharmaceuticals. 2012; 5 (4): 398–404.Zulkarneev R., Zagidullin N., Abdrahmanova G. et al. Ivabradine prevents heart rate acceleration in patients with chronic obstructive pulmonary disease and coronary heart disease after salbutamol inhalation. Pharmaceuticals. 2012; 5 (4): 398–404.Hanrahan J.P., Grogan D.R., Baumgartner R.A. et al. Arrhythmias in patients with chronic obstructive pulmonary disease (COPD): occurrence frequency and the effect of treatment with the inhaled longacting beta2agonists arfor moterol and salmeterol. Medicine (Baltimore). 2008; 87 (6): 319–328.Hanrahan J.P., Grogan D.R., Baumgartner R.A. et al. Arrhythmias in patients with chronic obstructive pulmonary disease (COPD): occurrence frequency and the effect of treatment with the inhaled longacting beta2agonists arfor moterol and salmeterol. Medicine (Baltimore). 2008; 87 (6): 319–328.Karvandi M., Piranfar M.A., Ghaffaripour M. et al. An alternative method for perioperative estimation of pulmonary artery systolic pressure by echocardiography. Shiraz E*Med. J. 2007; 8: 4:174–182.Karvandi M., Piranfar M.A., Ghaffaripour M. et al. An alternative method for perioperative estimation of pulmonary artery systolic pressure by echocardiography. Shiraz E*Med. J. 2007; 8: 4:174–182.Curkendall S.M., DeLuise C., Jones J.K. et al. Cardiovascular disease in patients with chronic obstructive pulmonary disease, Saskatchewan Canada cardiovascular disease in COPD patients. Ann. Epidemiol. 2006; 16: 63–70.Curkendall S.M., DeLuise C., Jones J.K. et al. Cardiovascular disease in patients with chronic obstructive pulmonary disease, Saskatchewan Canada cardiovascular disease in COPD patients. Ann. Epidemiol. 2006; 16: 63–70.Schneider C., Bothner U., Jick S.S., Meier C.R. Chronic obstructive pulmonary disease and the risk of cardiovascular diseases. Eur. J. Epidemiol. 2010; 25: 253–260.Schneider C., Bothner U., Jick S.S., Meier C.R. Chronic obstructive pulmonary disease and the risk of cardiovascular diseases. Eur. J. Epidemiol. 2010; 25: 253–260.Roque A.L., Valenti V.E., Massetti T. et al. Chronic obstructive pulmonary disease and heart rate variability: a literature update. Int. Arch. Med. 2014; 3 (7): 43.Roque A.L., Valenti V.E., Massetti T. et al. Chronic obstructive pulmonary disease and heart rate variability: a literature update. Int. Arch. Med. 2014; 3 (7): 43.Forfia P.R., Fisher M.R., Mathai S.C. et al. Tricuspid annular displacement predicts survival in pulmonary hypertension. Am. J. Respir. Crit. Care Med. 2006; 174 (9): 1034–1041.Forfia P.R., Fisher M.R., Mathai S.C. et al. Tricuspid annular displacement predicts survival in pulmonary hypertension. Am. J. Respir. Crit. Care Med. 2006; 174 (9): 1034–1041.Worth H., Fan Chung K., Felser K. et al. Cardio and cere brovascular safety of indacaterol vs formoterol, salmeterol, tiotropium and placebo in COPD. Respir. Med. 2011; 105: 571–579.Worth H., Fan Chung K., Felser K. et al. Cardio and cere brovascular safety of indacaterol vs formoterol, salmeterol, tiotropium and placebo in COPD. Respir. Med. 2011; 105: 571–579.Bateman E., Ferguson G.T., Barnes N. et al. Dual bron chodilation with QVA149 versus single bronchodilator therapy: the SHINE study. Eur. Respir. J. 2013; 42: 1484–1494.Bateman E., Ferguson G.T., Barnes N. et al. Dual bron chodilation with QVA149 versus single bronchodilator therapy: the SHINE study. Eur. Respir. J. 2013; 42: 1484–1494.Mahler D., Decramer M., D’Urzo A. et al. Dual bronchodilation with QVA149 reduces patientreported dyspnoea in COPD: the BLAZE study. Eur. Respir. J. 2014; 43: 1599–1609.Mahler D., Decramer M., D’Urzo A. et al. Dual bronchodilation with QVA149 reduces patientreported dyspnoea in COPD: the BLAZE study. Eur. Respir. J. 2014; 43: 1599–1609.Wedzicha J., Decramer M., Ficker J.H. et al. Analysis of chronic obstructive pulmonary disease exacerbations with the dual bronchodilator QVA149 compared with glycopy rronium and tiotropium (SPARK): a randomised, double blind, parallelgroup study. The Lancet. Lancet Respir. Med. 2013; 1 (3): 199–209.Wedzicha J., Decramer M., Ficker J.H. et al. Analysis of chronic obstructive pulmonary disease exacerbations with the dual bronchodilator QVA149 compared with glycopy rronium and tiotropium (SPARK): a randomised, double blind, parallelgroup study. The Lancet. Lancet Respir. Med. 2013; 1 (3): 199–209.Zhong N., Wang C., Zhou W. LANTERN: a randomized study of QVa149 versus salmeterol / fluticasone combination in patients with COPD. Int. J. COPD. 2015; 10: 1015–1026.Zhong N., Wang C., Zhou W. LANTERN: a randomized study of QVa149 versus salmeterol / fluticasone combination in patients with COPD. Int. J. COPD. 2015; 10: 1015–1026.

The authors declare that there are no conflicts of interest present.